case
infect
laboratori
confirm
suspect
among
laboratoryconfirm
case
casefat
rate
mortal
rate
case
laboratori
confirm
suspect
consid
although
previou
episod
mhf
involv
singl
distinct
strain
marv
outbreak
involv
least
genet
distinct
strain
marv
marv
resurfac
eastern
africa
absenc
decad
subsequ
take
much
time
reemerg
first
month
larg
outbreak
filovirallik
hemorrhag
fever
began
uig
provinc
northern
angola
immedi
thought
outbreak
like
caus
ebov
geograph
proxim
past
outbreak
ebov
infect
coupl
appar
high
casefat
rate
howev
earli
outbreak
found
caus
new
strain
marv
marv
angola
marvang
death
record
among
case
patient
reason
increas
lethal
new
strain
marv
present
unknown
signific
concern
sever
coagul
disord
one
promin
featur
filovir
infect
zair
ebov
zebov
previous
show
procoagul
tissu
factor
tf
contribut
develop
coagulopathi
recombin
nematod
anticoagul
protein
inhibitor
tf
pathway
provid
partial
postexposur
protect
rhesu
macaqu
surviv
prolong
diseas
cours
anim
associ
attenu
coagul
proinflammatori
respons
anim
respond
treatment
show
reduc
plasma
level
ddimer
lesspromin
fibrin
deposit
tissu
lower
plasma
level
interleukin
il
monocyt
chemoattract
protein
mcp
also
shown
dampen
proinflammatori
respons
case
human
endotoxemia
healthi
human
subject
coagul
deliber
provok
stimul
antithrombot
potenti
demonstr
phase
ii
trial
clinic
set
orthoped
surgeri
coronari
revascular
studi
evalu
pathogen
marvang
rhesu
macaqu
also
assess
efficaci
new
marv
strain
anim
studi
twelv
healthi
adult
rhesu
macaqu
macaca
mulatta
weigh
kg
use
studi
done
part
initi
studi
perform
confirm
virul
marvang
first
studi
macaqu
control
anim
inocul
intramuscular
inject
pfu
marvang
provid
p
rollin
center
diseas
control
prevent
atlanta
ga
marvang
strain
use
origin
obtain
serum
sampl
fatal
infect
human
pass
twice
vero
cell
initi
studi
confirm
virul
marvang
second
studi
evalu
util
postexposur
treatment
modal
regimen
follow
ident
describ
elsewher
zebov
infect
brief
anim
expos
pfu
marvang
mean
intramuscular
inject
anim
anim
subject
treat
subcutan
inject
mgkg
bodi
weight
daili
obtain
previous
corva
intern
begin
min
viral
challeng
continu
day
exposur
marvang
three
macaqu
serv
experiment
control
anim
receiv
equival
volum
steril
pb
accord
regimen
use
anim
blood
sampl
collect
challeng
day
challeng
blood
sampl
also
collect
time
death
possibl
research
conduct
complianc
anim
welfar
act
feder
statu
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
facil
research
conduct
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
rockvil
md
viru
detect
level
infecti
marvang
determin
plaqu
assay
vero
cell
blood
sampl
select
tissu
describ
elsewher
marv
hematolog
serum
biochemistri
coagul
test
hematolog
serum
biochemistri
analyz
describ
elsewher
use
laserbas
hematolog
analyz
coulter
electron
piccolo
pointofcar
blood
analyz
abaxi
respect
plasma
level
ddimer
protein
c
measur
detail
studi
report
cytokin
chemokin
product
cytokin
chemokin
level
monkey
plasma
determin
use
human
cytokin
beadarray
assay
kit
biosourc
bioplex
system
biorad
accord
manufactur
direct
cytokin
chemokin
assay
includ
eotaxin
granulocytemacrophag
colonystimul
factor
interferon
ifn
ifng
receptor
antagonist
receptor
ifnginduc
macrophag
inflammatori
protein
mip
ifnginduc
monokin
rant
tumor
necrosi
factora
rnase
protect
assay
multiprob
rnase
protect
assay
pharmingen
done
use
peripher
blood
mononuclear
cell
pbmc
collect
monkey
exposur
marvang
describ
elsewher
level
mrna
express
measur
analysi
band
intens
phosphor
screen
typhoon
note
fever
defin
temperatur
higher
baselin
least
higher
baselin
rash
defin
follow
mild
focal
area
petechia
cover
skin
moder
focal
area
petechia
cover
skin
sever
focal
area
petechia
andor
echymosi
cover
skin
lymphopenia
thrombocytopenia
defin
decreas
number
lymphocyt
platelet
respect
leukocytosi
defin
increas
white
blood
cell
wbc
baselin
also
wbc
count
f
increas
ff
increas
fff
increas
alp
alkalin
phosphatas
alt
alanin
aminotransferas
ast
aspart
aminotransferas
bun
blood
urea
nitrogen
cre
creatinin
ggt
gglutamyltransferas
glu
glucos
tbil
total
bilirubin
variablemod
imag
molecular
dynam
band
intens
analyz
use
imagequ
softwar
molecular
dynam
chang
tf
mrna
express
calcul
basi
ratio
express
housekeep
gene
flow
cytometri
approxim
pbmc
stain
cellsurfac
marker
tf
express
tf
stain
done
incub
cell
antitf
mous
monoclon
antibodi
human
tf
american
diagnostica
follow
fluorescein
isothiocyanatelabel
goat
antimous
antibodi
sigmaaldrich
cellsurfac
stain
done
describ
elsewher
confirm
gate
cell
popul
data
present
percentag
posit
cell
gate
cell
popul
sampl
run
facscalibur
flow
cytomet
analyz
use
bd
cellquest
pro
softwar
bd
bioscienc
histopatholog
immunohistochemistri
tissu
sampl
collect
fix
immers
neutral
buffer
formalin
sampl
process
histopatholog
phosphotungst
acid
hematoxylin
ptah
stain
demonstr
polymer
fibrin
immunohistochemistri
previous
describ
use
mous
monoclon
antibodi
marv
glycoprotein
iii
dilut
statist
analysi
data
collect
studi
analyz
mean
logrank
test
comparison
surviv
rate
wilcoxon
rank
sum
test
comparison
mean
time
death
mean
level
solubl
mediat
compar
use
student
test
investig
pathogen
potenti
marvang
rhesu
macaqu
control
anim
experiment
infect
intramuscular
inject
pfu
marvang
result
previou
studi
use
strain
marv
infect
rhesu
macaqu
similar
experiment
condit
ie
subcutan
intramuscular
inject
dose
estim
pfu
suggest
rhesu
macaqu
begin
show
clinic
evid
infect
around
day
usual
die
day
challeng
howev
initi
pilot
studi
diseas
appear
progress
rapidli
anim
began
show
clinic
sign
ill
day
tabl
characterist
featur
marv
infect
includ
fever
cutan
rash
lymphopenia
andor
elev
circul
level
enzym
associ
organ
dysfunct
promin
anim
day
thrombocytopenia
promin
featur
ebola
hemorrhag
fever
ehf
nonhuman
primat
preval
anim
howev
modest
declin
level
platelet
consist
find
marv
studi
macaqu
seen
day
infect
decreas
plasma
level
protein
c
concomit
increas
plasma
level
ddimer
observ
marvanginfect
macaqu
appear
mark
previous
describ
zebovinfect
macaqu
increas
level
tf
transcript
detect
pbmc
marvanginfect
macaqu
appear
develop
later
diseas
cours
report
zebovinfect
macaqu
marvinfect
anim
succumb
challeng
macaqu
die
day
control
anim
macaqu
die
day
control
anim
gener
macroscop
microscop
lesion
similar
find
previous
describ
marv
infect
human
andor
nonhuman
primat
howev
liver
appear
bit
affect
marvang
higher
organ
infect
titer
evid
necrosi
inflamm
observ
marv
musokeinfect
anim
twg
unpublish
data
much
involv
liver
zebovinfect
macaqu
brief
liver
sever
reticul
discolor
figur
histolog
find
includ
hepatocellular
degener
necrosi
occasion
neutrophil
monocyt
inflamm
figur
anim
although
signific
pauciti
immunohistochem
data
tissu
human
nonhuman
primat
infect
marv
distribut
antigen
macaqu
consist
find
report
human
case
marv
infect
strain
ravn
immunohistochem
stain
marv
antigen
particularli
promin
liver
figur
splenic
red
pulp
anim
similarli
organ
infect
titrat
show
liver
spleen
particularli
high
load
infecti
marvang
mean
titer
log
pfug
respect
untreat
control
anim
mean
organ
infect
titer
marvang
tissu
rang
log
pfug
data
shown
immunoposit
stain
promin
hepatocyt
figur
kupffer
cell
liver
also
monocyt
macrophag
fibroblast
tissu
examin
addit
anim
show
lesion
consist
find
human
case
marv
infect
includ
viral
infect
adren
cortic
medullari
cell
figur
pancreat
islet
cell
figur
also
investig
cytokin
chemokin
respons
marvanginfect
anim
sinc
mani
inflammatori
mediat
play
import
role
interact
coagul
system
inflamm
infect
review
increas
level
sever
cytokin
chemokin
detect
termin
stage
diseas
anim
includ
eotaxin
test
concept
blockad
tf
pathway
may
benefici
marvang
infect
next
treat
rhesu
macaqu
subcutan
inject
mgkg
bodi
weight
daili
subject
rhesu
macaqu
steril
salin
control
anim
begin
min
marvang
challeng
continu
day
exposur
consist
result
pilot
experi
macaqu
treat
placebo
studi
die
day
marvang
challeng
contrast
anim
subject
surviv
marvang
challeng
wherea
remain
anim
die
day
figur
anim
surviv
challeng
remain
healthi
year
mean
surviv
time
anim
succumb
marvang
challeng
day
compar
day
cohort
control
anim
nearli
prolong
surviv
macaqu
statist
signific
p
p
day
challeng
anim
group
show
clinic
featur
marv
infect
consist
control
anim
tabl
primari
differ
group
slower
develop
macular
rash
anim
versu
control
anim
figur
result
marvang
plasma
viremia
summar
figur
anim
becam
virem
littl
differ
observ
cohort
anim
die
control
anim
anim
surviv
subject
much
lower
plasma
viremia
anim
level
subject
never
exceed
log
pfuml
subject
becam
avirem
day
comparison
plasma
viremia
cohort
nonsurvivor
control
anim
exceed
log
pfuml
day
determin
effect
develop
coagulopathi
marvang
hemorrhag
fever
monitor
rang
factor
involv
regul
coagul
fibrinolysi
result
plasma
viremia
littl
differ
coagul
factor
protein
c
activ
figur
level
ddimer
figur
note
cohort
nonsurvivor
control
anim
found
ebov
infect
macaqu
plasma
level
ddimer
increas
marvanginfect
anim
protein
c
activ
substanti
decreas
convers
consist
result
plasma
viremia
sole
anim
surviv
marvang
challeng
subject
much
lower
plasma
level
ddimer
protein
c
activ
chang
show
increas
percentag
tfposit
cell
monocyt
gate
primarili
later
stage
infect
defin
day
later
anim
studi
howev
differ
anim
placebotr
control
anim
found
histolog
evalu
perform
anim
succumb
marvang
infect
determin
extent
drug
block
format
fibrin
howev
determin
ptah
stain
differ
seen
amount
polymer
fibrin
tissu
anim
compar
control
anim
although
polymer
fibrin
common
find
tissu
zebovinfect
macaqu
polymer
fibrin
observ
sporad
marvanginfect
control
anim
studi
figur
differ
plasma
level
cytokin
chemokin
found
control
anim
nonsurvivor
figur
substanti
differ
note
respons
survivor
subject
versu
nonsurvivor
studi
contrast
nonsurvivor
subject
increas
plasma
level
eotaxin
cours
infect
present
licens
vaccin
treatment
mhf
urgent
need
effect
countermeasur
mhf
reinforc
recent
outbreak
angola
height
outbreak
interest
evalu
potenti
postexposur
treatment
mhf
express
number
intern
health
care
organ
interest
driven
studi
rhesu
macaqu
show
tfpathway
inhibitor
postexposur
efficaci
ehf
safe
use
varieti
medic
applic
current
proofofconcept
studi
evalu
efficaci
postexposur
treatment
marvang
hemorrhag
fever
administ
rhesu
macaqu
shortli
challeng
marvang
result
studi
surviv
increas
mean
time
death
impress
result
obtain
studi
zebovinfect
rhesu
macaqu
treat
surviv
increas
mean
time
death
even
though
studi
design
ident
nonetheless
surviv
benefici
effect
achiev
otherwis
uniformli
lethal
model
viru
challeng
although
mani
common
pathogenesi
ehf
mhf
macaqu
observ
potenti
import
differ
marvanginfect
macaqu
use
studi
tf
upregul
marvanginfect
macaqu
howev
level
tf
strike
note
zebovinfect
macaqu
differ
enc
level
tf
may
contribut
reduc
efficaci
marvanginfect
macaqu
compar
zebovinfect
macaqu
act
inhibit
tffactor
viia
pathway
thu
tf
import
develop
coagulopathi
marvang
infect
macaqu
block
tf
pathway
may
much
impact
mitig
diseas
studi
need
order
systemat
dissect
differ
tf
product
similar
variabl
degre
tf
express
differ
coagulopathi
note
marvanginfect
zebovinfect
macaqu
particular
deposit
polymer
fibrin
promin
patholog
find
tissu
zebovinfect
macaqu
less
frequent
observ
tissu
marvanginfect
macaqu
differ
includ
degre
hepatocyt
infect
necrosi
inflamm
liver
promin
marvanginfect
anim
report
zebovinfect
macaqu
fact
mean
viru
titer
liver
marvanginfect
macaqu
exceed
log
pfug
nearli
log
pfug
typic
seen
ebovinfect
macaqu
marvanginfect
macaqu
coagul
disord
may
exacerb
decreas
synthesi
coagul
protein
due
sever
hepatocellular
necrosi
thrombocytopenia
induct
tf
pathway
blood
coagul
known
abil
protect
hepatocyt
function
lower
efficaci
marvang
infect
may
relat
increas
liver
damag
seen
marvanginfect
macaqu
versu
seen
zebovinfect
macaqu
anoth
explan
reduc
efficaci
marvang
hemorrhag
fever
may
rapid
diseas
cours
associ
marvang
infect
therapeut
window
rhesu
macaqu
model
marvang
infectionthat
mean
time
death
dayswa
day
shorter
therapeut
window
zebovinfect
rhesu
macaqu
day
whether
relat
modal
would
util
treatment
infect
caus
marv
strain
diseas
cours
may
protract
unknown
reason
appar
increas
virul
marvang
human
nonhuman
primat
unknown
one
consider
regard
studi
macaqu
passag
histori
viru
strain
use
studi
versu
passag
histori
marv
strain
use
studi
passag
histori
marvang
low
ie
passag
human
serum
best
direct
comparison
ravn
strain
marv
also
low
passag
histori
passag
human
serum
shown
inject
rhesu
macaqu
studi
marv
ravn
use
higher
challeng
dose
pfu
anim
surviv
anim
die
day
challeng
result
suggest
passag
histori
may
explain
increas
virul
marvang
rel
marv
strain
growth
curv
compar
marvang
marv
strain
includ
musok
ravn
primari
human
monocyt
macrophag
show
differ
repli
unpublish
data
howev
plasma
viremia
detect
earlier
marvanginfect
macaqu
macaqu
infect
marv
musok
thu
although
appar
differ
fit
found
marv
strain
vitro
elimin
possibl
marvang
better
abl
replic
andor
control
host
immun
respons
nonhuman
primat
although
nucleotid
differ
marvang
east
african
strain
marv
eg
musok
ozolin
popp
key
genet
differ
somewher
among
like
factor
contribut
appar
increas
virul
marvang
primat
although
genet
dispar
marv
strain
lineag
contain
marvang
inde
minim
studi
shown
even
singleamino
acid
chang
alter
cell
tropism
viral
pathogen
number
virus
includ
lymphocyt
choriomening
viru
dengu
viru
sever
acut
respiratori
syndrom
viru
human
immunodefici
viru
conclus
show
treatment
result
statist
signific
increas
mean
time
death
among
rhesu
macaqu
infect
marvang
protect
anim
lethal
infect
although
result
studi
promis
result
similar
studi
use
treat
zebovinfect
rhesu
macaqu
nonetheless
encourag
provid
possibl
treatment
option
mhf
surviv
anim
challeng
marvang
associ
attenu
coagul
proinflammatori
respons
find
consist
surviv
zebovinfect
macaqu
zebovinfect
macaqu
treat
recombin
human
activ
protein
c
moreov
sever
sepsi
human
surviv
correl
biomark
includ
plasma
level
protein
c
find
support
concept
target
underli
mechan
ill
identifi
studi
pathogenesi
